Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: POAG Clear all
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jun 26, 2026, 8:21 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

NCT05695027
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Dietary supplements - Nicotinamide and Pyruvate, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

NCT04747808
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
LL-BMT1
Drug
Lead sponsor
MediPrint Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT03233308
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%, Placebo Comparator
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

NCT00051155
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jun 26, 2026, 8:21 AM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

The Effects of an Antioxidant Formulation on Ocular Blood Flow

NCT01930487
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
dietary supplement with antioxidants, Placebo
Dietary Supplement
Lead sponsor
ScienceBased Health
Industry
Eligibility
30 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181
View directory record Official record
Conditions
Glaucoma, Angle-Closure, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04024072
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Jun 26, 2026, 8:21 AM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Jun 26, 2026, 8:21 AM EDT
Recruiting Not applicable Interventional

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

NCT05564091
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
Device · Procedure
Lead sponsor
Nova Eye, Inc.
Industry
Eligibility
55 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jun 26, 2026, 8:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

NCT06822738
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
XEN63 Glaucoma Treatment System
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Glendale, Arizona • Culver City, California • Petaluma, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 8:21 AM EDT
Terminated No phase listed Observational

Development and Validation of a Model to Predict Fast Progression in Glaucoma

NCT04454190
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions
Collection of genetic material
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
1,152 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

NCT03365778
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 90 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

NCT00824824
View directory record Official record
Conditions
Glaucoma
Interventions
Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Jun 26, 2026, 8:21 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902
View directory record Official record
Conditions
Glaucoma
Interventions
BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Glendale, California • Newport Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

NCT00047515
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the United States, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jun 26, 2026, 8:21 AM EDT
Recruiting Not applicable Interventional

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

NCT06057051
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Infinite
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 26, 2026, 8:21 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

NCT05024695
View directory record Official record
Conditions
Glaucoma
Interventions
MINIject™ Implant
Device
Lead sponsor
iSTAR Medical
Industry
Eligibility
46 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
28
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jun 26, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device

NCT02016898
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Placement of the sponge, Mitomycin-C
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Jun 26, 2026, 8:21 AM EDT